Medivir presents at the Rodman & Renshaw Conference

Medivir has participated in, and was yesterday presented before, the Rodman & Renshaw Annual Global Investment Conference in New York, USA. The presentation is now available on our website:, under the IR&Media/Latest Events tab. For additional information, please contact Rein Piir, CFO & VP Investor Relations, Medivir +46 708 53 72 92. For more on Medivir, please see the company website:


About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


Documents & Links